Common over-the-counter sits at the center of this dementia and brain health question.
Several of the most familiar drugs in American medicine cabinets — Sudafed, Benadryl, Pepto-Bismol, and codeine-based cough syrups — are banned, restricted, or require a prescription in countries around the world. The reasons vary from concerns about methamphetamine production to evidence of rare but serious neurological harm, including conditions that reduce blood supply to the brain. For anyone managing dementia care or prioritizing brain health, these international restrictions offer a revealing lens into how different regulatory bodies weigh the neurological risks of substances millions of Americans take without a second thought. The drug drawing the most attention right now is pseudoephedrine, the active ingredient in Sudafed, Sinutab, and Actifed. Japan bans it outright under its Stimulants Control Law.
Mexico has prohibited it entirely since November 23, 2007. Belgium pulled it from over-the-counter shelves as of November 1, 2024, and France has imposed similar prescription requirements. The European Medicines Agency found that pseudoephedrine-containing medicines can cause posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome — both conditions involving reduced blood supply to the brain. These are not abstract pharmacological footnotes. They are the kind of vascular events that clinicians increasingly recognize as contributors to cognitive decline. This article walks through the specific drugs affected, the countries enforcing restrictions, the neurological reasoning behind these bans, and what all of it means for people caring for aging family members or managing their own brain health over the long term.
Table of Contents
- Why Are Common Over-the-Counter Drugs Like Sudafed Banned in Some Countries?
- The Neurological Risks Behind Pseudoephedrine Restrictions
- Benadryl, Diphenhydramine, and the Anticholinergic Problem
- What Caregivers Should Know About Pepto-Bismol and Bismuth Neurotoxicity
- Codeine and Controlled Cough Medicines — A Hidden Risk for Older Adults
- What Qatar and the UAE Teach Us About Medication Assumptions
- Where International Drug Regulation Is Heading
- Conclusion
- Frequently Asked Questions
Why Are Common Over-the-Counter Drugs Like Sudafed Banned in Some Countries?
The short answer is that different countries apply different risk thresholds, and some have decided the dangers outweigh the convenience. Pseudoephedrine sits at the center of this debate for two distinct reasons. First, it is a precursor chemical for methamphetamine synthesis, which is why Mexico banned it entirely in 2007 and why Japan classifies any medicine containing more than ten percent pseudoephedrine as a “Stimulant Raw Material” under its Stimulants Control Law. Violations in Japan can result in arrest and imprisonment — not a fine, not a confiscation, but actual jail time. Second, and more relevant to brain health, the European Medicines Agency identified that pseudoephedrine carries a risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS). Both conditions involve the sudden narrowing or dysfunction of blood vessels in the brain, and both can produce symptoms that mimic stroke or transient ischemic attack. Compare how the United States handles this with Belgium’s approach. In the U.S., pseudoephedrine was moved behind the pharmacy counter after the Combat Methamphetamine Epidemic Act of 2005, but it remains available without a prescription in most states.
Belgium, as of November 2024, requires a full prescription. France followed a similar path. The European approach reflects a precautionary principle — if a drug can cause rare but serious brain vascular events, and safer alternatives exist, then unrestricted access is hard to justify. The American approach leans more heavily on individual choice and assumes informed consumers can manage the risk. For families dealing with dementia or cognitive decline, this distinction matters. Older adults are more vulnerable to vascular events in the brain. A medication that a healthy thirty-year-old takes without issue during cold season may pose a meaningfully different risk profile for a seventy-five-year-old with existing cerebrovascular concerns. The fact that entire countries have decided the risk is unacceptable should at least prompt a conversation with a physician before reaching for the Sudafed.
The Neurological Risks Behind Pseudoephedrine Restrictions
Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome sound obscure, but their mechanics are straightforward. PRES involves swelling in the brain caused by a failure of the blood-brain barrier’s ability to regulate pressure. Symptoms can include severe headaches, confusion, seizures, and vision changes. RCVS involves the sudden, temporary narrowing of arteries in the brain, producing thunderclap headaches and, in serious cases, stroke. Both conditions are described as “reversible,” but that word does important work — reversal depends on early recognition and stopping the offending agent. If the condition goes unrecognized or is misattributed to something else, the damage can become permanent. The European Medicines Agency’s referral on pseudoephedrine-containing medicines flagged these risks specifically because they were appearing in post-marketing surveillance data.
These were not theoretical concerns identified in a lab. They were adverse events reported in real patients taking standard doses of commercially available cold medications. The EMA’s recommendation led directly to the prescription-only reclassification in Belgium and France and prompted broader review across the European Union. However, it is important to note a limitation: these events remain rare at a population level. Most people who take pseudoephedrine will not develop PRES or RCVS. The risk calculus changes, though, for people who already have hypertension, cardiovascular disease, or cerebrovascular vulnerability — categories that overlap heavily with the population at risk for dementia. If someone in your care has high blood pressure or a history of transient ischemic attacks, even a “rare” vascular event triggered by a cold medicine is a risk worth avoiding entirely. Safer decongestant alternatives, including saline nasal irrigation and intranasal corticosteroids, exist and do not carry these vascular warnings.
Benadryl, Diphenhydramine, and the Anticholinergic Problem
Diphenhydramine — the active ingredient in Benadryl — faces its own set of international restrictions, though for somewhat different reasons. Japan allows diphenhydramine only in tablets containing ten milligrams or less. A standard U.S. Benadryl tablet contains twenty-five milligrams, which means it exceeds Japan’s limit and would be confiscated at customs. The United Arab Emirates classifies diphenhydramine as a controlled substance, and possession without a permit can result in imprisonment. Together, Sudafed and Benadryl account for ninety-four percent of all medication-related arrests involving U.S. citizens in Japan, according to travel advisory reports. For the dementia care community, diphenhydramine carries a separate and well-documented concern: its anticholinergic properties.
Anticholinergic drugs block acetylcholine, a neurotransmitter critical for memory and learning — the same neurotransmitter that Alzheimer’s disease progressively destroys. Multiple long-term studies have linked sustained anticholinergic use to increased dementia risk. A widely cited study from the University of Washington, published in JAMA Internal Medicine, found that cumulative anticholinergic use over several years was associated with a significantly higher risk of developing dementia. Benadryl is one of the most commonly used anticholinergic drugs in the United States precisely because it is cheap, familiar, and available everywhere. The countries that restrict diphenhydramine are not necessarily doing so because of the dementia connection — Japan’s restrictions are largely about controlling stimulant precursors and managing drug potency, and the UAE’s approach reflects broader narcotics control policy. But the practical effect is the same: populations in those countries have less casual exposure to a drug that many neurologists and geriatricians in the United States have been quietly warning about for years. The irony is difficult to ignore. The restrictions motivated by drug control policy may be incidentally protecting brain health in ways that the U.S. regulatory framework does not.
What Caregivers Should Know About Pepto-Bismol and Bismuth Neurotoxicity
Bismuth subsalicylate, the active ingredient in Pepto-Bismol, is one of the most widely used stomach remedies in America. It is also expressly banned in France and Denmark. It is unavailable over the counter or at pharmacies in Germany, Italy, and Switzerland. Japan and Chile either do not carry it or severely limit its availability. The reason traces back to a health crisis in France during the 1970s, when high levels of bismuth were linked to neurotoxicity — specifically, brain damage in patients with kidney problems who were unable to clear the metal efficiently from their bodies. The comparison here is instructive. In the United States, Pepto-Bismol is marketed as a gentle, pink, family-friendly remedy. In much of Europe, the active ingredient is treated as a neurological hazard.
The difference is not that European stomachs are more delicate. It is that French regulators, having witnessed cases of bismuth-related encephalopathy firsthand, decided the risk was not worth the benefit when other antacids and antidiarrheals were available. The European Medicines Agency has also raised concerns about salicylates — the other half of bismuth subsalicylate — posing risks to children recovering from viral infections, echoing the Reye’s syndrome warnings that already exist for aspirin. For caregivers managing an older adult’s medication regimen, this matters in a practical way. Many people with dementia experience gastrointestinal issues, whether from the disease itself, from medications, or from dietary changes. Reaching for Pepto-Bismol seems harmless. But if that person also has compromised kidney function — which is common in older adults — the bismuth accumulation risk is real. It is not the kind of thing that produces an immediate crisis. It is the kind of thing that contributes to a slow, hard-to-diagnose worsening of confusion and cognitive function, which in a person already dealing with dementia may simply be attributed to disease progression rather than a treatable cause.
Codeine and Controlled Cough Medicines — A Hidden Risk for Older Adults
Codeine-based cough syrups and combination painkillers like Tylenol with Codeine occupy an unusual regulatory space. In some U.S. states, low-dose codeine products can still be obtained without a prescription or with minimal pharmacist oversight. Internationally, the picture is far more restrictive. The UAE classifies codeine as a controlled substance, and carrying it without a permit can result in one to three years in prison. Japan, Greece, and Indonesia either control codeine tightly or ban it outright. The brain health concern with codeine is twofold.
As an opioid, even a mild one, it carries sedation and cognitive impairment risks that are amplified in older adults. The American Geriatrics Society’s Beers Criteria — the gold-standard list of medications to avoid in older adults — includes opioids for good reason. Falls, confusion, respiratory depression, and constipation are all dose-dependent risks that become more dangerous as the brain and body age. For a person with existing cognitive impairment, codeine can deepen confusion in ways that look like a sudden worsening of dementia rather than a drug side effect. The warning here is straightforward but often overlooked: just because a cough syrup is available without a prescription does not mean it is appropriate for someone with dementia or significant cognitive decline. The countries that restrict codeine more aggressively are, in effect, making it harder for vulnerable populations to accidentally expose themselves to an opioid. In the United States, that gatekeeping falls almost entirely on caregivers and family members, many of whom do not realize that a familiar cough remedy contains an opioid at all.
What Qatar and the UAE Teach Us About Medication Assumptions
Qatar classifies over-the-counter cold and cough remedies as controlled substances, requiring a prescription for medications that Americans buy by the handful during flu season. The UAE’s strict controls on diphenhydramine and codeine have already been noted. These policies reflect a fundamentally different philosophy about who should decide when a drug is appropriate — one that places that decision with a physician rather than with the consumer.
For caregivers, there is a useful principle buried in these policies. The assumption that over-the-counter means safe is one of the most dangerous shortcuts in managing an older adult’s health. Every medication a person with dementia takes should be evaluated not against the standard of “is this available without a prescription” but against the standard of “does my loved one’s physician know about this, and have they confirmed it is appropriate given everything else in the picture.” The countries that require prescriptions for common cold medicines are not being paternalistic for its own sake. They are acknowledging that the risk-benefit calculation changes depending on the patient — a principle that applies with particular force to people with compromised brain function.
Where International Drug Regulation Is Heading
The trend across Europe and parts of Asia is clearly toward greater restriction of medications that carry neurological or vascular risks, even when those risks are rare. Belgium’s 2024 reclassification of pseudoephedrine, the EMA’s ongoing review of decongestant safety, and Japan’s strict import controls all point in the same direction. As post-marketing surveillance improves and more data on long-term cognitive effects accumulates, it is likely that additional common medications will face reclassification in the coming years.
For the brain health community, this trajectory offers both a caution and an opportunity. The caution is that medications currently considered benign may not stay that way as evidence evolves. The opportunity is that every restriction imposed elsewhere is a signal worth paying attention to — a reason to ask questions, consult with a neurologist or geriatrician, and think carefully before assuming that a drug’s over-the-counter status is a reliable proxy for its safety in an aging brain.
Conclusion
The patchwork of international drug bans reveals something American consumers rarely consider: the over-the-counter label is not a universal safety guarantee. It is a regulatory classification that varies from country to country based on different risk tolerances, different historical experiences, and different philosophies about patient autonomy. Pseudoephedrine’s links to brain vascular events, diphenhydramine’s anticholinergic burden, bismuth’s neurotoxicity in vulnerable kidneys, and codeine’s opioid sedation are all documented risks that other countries have decided warrant tighter control than the United States currently imposes. For anyone managing their own brain health or caring for someone with cognitive decline, the practical takeaway is to treat every medication — prescription or not — as something that deserves scrutiny.
Talk to a physician or pharmacist before adding any over-the-counter drug to an older adult’s regimen. Look up the anticholinergic risk score. Ask whether a decongestant is truly necessary or whether a saline rinse would suffice. The countries that ban these drugs are not overreacting. They are responding to evidence that Americans have access to as well — if they choose to look.
Frequently Asked Questions
Is Sudafed actually dangerous, or are other countries just being overly cautious?
The European Medicines Agency identified real cases of posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome in patients taking pseudoephedrine at standard doses. These are rare events, but they involve reduced blood supply to the brain and can cause lasting harm if not caught early. For people with hypertension or cerebrovascular risk factors — common in older adults — the risk is more significant.
Can I bring Benadryl to Japan?
Only if the tablets contain ten milligrams or less of diphenhydramine. Standard U.S. Benadryl tablets contain twenty-five milligrams and will be confiscated at customs. Sudafed and Benadryl together account for ninety-four percent of medication-related arrests of U.S. citizens in Japan.
Why is Pepto-Bismol banned in France?
A health scare in France in the 1970s linked high levels of bismuth to neurotoxicity, particularly brain damage in patients with kidney problems. France and Denmark expressly ban the active ingredient, bismuth subsalicylate, and it is not available over the counter in Germany, Italy, or Switzerland.
Should people with dementia avoid all over-the-counter cold medicines?
Not necessarily all, but many common ones carry risks that are amplified in people with cognitive decline. Diphenhydramine is anticholinergic, pseudoephedrine carries vascular risks, and codeine is a sedating opioid. Any of these can worsen confusion or mimic disease progression. Always consult a physician before giving cold or allergy medicines to someone with dementia.
What are safer alternatives to these restricted medications?
For congestion, saline nasal irrigation and intranasal corticosteroids avoid the vascular risks of pseudoephedrine. For allergies, second-generation antihistamines like cetirizine or loratadine have far lower anticholinergic burden than diphenhydramine. For stomach issues, alternatives to bismuth subsalicylate include simethicone for gas and loperamide for diarrhea, though all should be reviewed with a doctor for older adults.
Are there U.S. efforts to restrict any of these drugs further?
There is no current legislative push to reclassify pseudoephedrine, diphenhydramine, or bismuth subsalicylate to prescription-only status in the United States. However, the American Geriatrics Society’s Beers Criteria already recommends against several of these medications in older adults, and many geriatricians actively counsel patients to avoid them.
You Might Also Like
- This Drug for PCOS Is Being Questioned After New Research
- This Drug Is Given Intravenously for a Condition Most People Take Orally
- This Blood Cancer Drug Is Changing How Hematologists Think About Relapse
For more, see NIH MedlinePlus — dementia.
